X0206 3 2017-11-16 0 0001604950 scPharmaceuticals Inc. SCPH 0001589314 5AM Partners IV, LLC 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001589315 5AM Ventures IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001593361 5AM Co-Investors IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001598549 Schwab Andrew J. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001240357 DIEKMAN JOHN D 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001219014 ROCKLAGE SCOTT M 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 Series A Preferred Stock Common Stock 10649003 I by 5AM Ventures IV, LP Series B Preferred Stock Common Stock 7263649 I by 5AM Ventures IV, LP Series A Preferred Stock Common Stock 443708 I by 5AM Co-Investors IV, LP Series B Preferred Stock Common Stock 302652 I by 5AM Co-Investors IV, LP All series of Convertible Preferred Stock will automatically convert into scPharmaceuticals Inc. common stock on a 7.180193-for-1 basis immediately prior to the closing of the initial public offering and have no expiration date. 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, LP and 5AM Co-Investors IV, LP. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Exhibit 24 - Power of Attorney /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Partners IV, LLC 2017-11-16 /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Ventures IV, LLC 2017-11-16 /s/ Courtney Gaughan, Attorney-in-Fact for 5AM Co-Investors IV, LLC 2017-11-16 /s/ Andrew J. Schwab 2017-11-16 /s/ John D. Diekman 2017-11-16 /s/ Scott M. Rocklage 2017-11-16